title: The comparative effects of single intravenous doses of omeprazole and famotidine on intragastric pH.
abstract: BACKGROUND
  The ideal medication for the treatment of acid-related diseases, for example, hemorrhagic ulcers and stress-related gastric bleeding, should have a rapid onset of action to promote hemostasis and alleviate symptoms. The aim of our study was to investigate the inhibitory effects on gastric acid secretion after single intravenous administrations of omeprazole 20mg and famotidine 20 mg.
  
  
  METHODS
  Ten healthy Helicobacter pylori-negative male subjects participated in this randomized, double-masked, two-way crossover study. Intragastric pH was monitored continuously for 4 h after a single intravenous administration of omeprazole 20 mg and after a single intravenous administration of famotidine 20 mg. The administration of the two agents was separated by a 7-day washout period.
  
  
  RESULTS
  In all ten subjects, the length of time that intragastric pH remained over 3, during the 0- to 3- and 0- to 4-h study periods, was greater after famotidine treatment than after treatment with omeprazole, and famotidine increased the average pH during the 0 to 3- and 0 to 4-h study periods significantly more than omeprazole did. During the 4-h study period, famotidine provided a longer duration of pH of more than 2, 3, 3.5, 4, 5, 6, and 7, compared to omeprazole.
  
  
  CONCLUSIONS
  In Helicobacter pylori-negative healthy male subjects, an intravenous dose of 20 mg famotidine increased intragastric pH more rapidly than intravenous omeprazole 20 mg.
authors.affiliation: The Third Department of Internal Medicine, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
authors.forename: Yasunobu
authors.initials: Y
authors.lastname: Abe
authors.forename: Masahiko
authors.initials: M
authors.lastname: Inamori
authors.forename: Jun-Ichi
authors.initials: J
authors.lastname: Togawa
authors.forename: Taisuke
authors.initials: T
authors.lastname: Kikuchi
authors.forename: Kenichi
authors.initials: K
authors.lastname: Muramatsu
authors.forename: Gaku
authors.initials: G
authors.lastname: Chiguchi
authors.forename: Harunobu
authors.initials: H
authors.lastname: Kawamura
authors.forename: Noritoshi
authors.initials: N
authors.lastname: Kobayashi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kirikoshi
authors.forename: Takashi
authors.initials: T
authors.lastname: Sakaguchi
authors.forename: Tomoo
authors.initials: T
authors.lastname: Takamura
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nakajima
authors.forename: Norio
authors.initials: N
authors.lastname: Ueno
authors.forename: Hisahiko
authors.initials: H
authors.lastname: Sekihara
mesh_terms: D000328:Adult; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000494:pharmacology*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D015738:Famotidine / Q000008:administration & dosage / Q000494:pharmacology*; D005744:Gastric Acid / Q000378:metabolism; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007275:Injections, Intravenous; D008297:Male; D009853:Omeprazole / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D015738:Famotidine; D009853:Omeprazole